|
|
||||||||
RECEPTORS AND SIGNAL TRANSDUCTION
1UCD Conway Institute, University College Dublin, Dublin, Ireland; 2Centre de Recherche en Rhumatologie-Immunologie du Centre Hospitalier de lUniversité Laval, Quebec City, Quebec, Canada; and 3Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
Submitted 21 June 2005 ; accepted in final form 29 September 2005
| ABSTRACT |
|---|
|
|
|---|
. Transfection of HeLa cells with truncated amphiregulin promoter reporter constructs revealed that a 37-bp segment upstream from the TATA box retained hypoxic sensitivity. This sequence contains an evolutionarily conserved cAMP response element (CRE) that constitutively binds the CRE binding protein (CREB). Deletion of the CRE abolished sensitivity to hypoxia. Thus hypoxia promotes intestinal epithelial amphiregulin expression in a CRE-dependent manner, an event that may contribute to increased proliferation. These data also further support a role for CREB as an HIF-independent hypoxia-responsive transcription factor in the regulation of intestinal epithelial gene expression. adenosine 3',5'-cyclic monophosphate response element binding protein; transcription; cancer
While investigating global gene expression in intestinal epithelial cells in response to hypoxia, we (13) identified increased expression levels of known HIF-1-dependent genes such as adrenomedullin and ITF (14, 33). However, this work also revealed increased expression of a number of genes not previously associated with HIF-1-dependent regulation. These included amphiregulin, a glycoprotein that binds to and activates the EGF receptor (EGFR) to regulate growth and proliferation of epithelial, smooth muscle, and neural stem cells (10, 19). A role for amphiregulin has been proposed in wound healing and tumor development, two events in which hypoxia is a vital component (35, 39, 44). Increased amphiregulin expression has been associated with a number of tumors (8, 28, 34); however, the mechanism of transcriptional upregulation is less well understood. Recent work has demonstrated the upregulation of amphiregulin in bronchial epithelial cells in response to fine particulate matter in a manner inhibited by antioxidant treatment (3). Lee et al. (24) also demonstrated a role for the Wilms tumor suppressor transcription factor (WT1) in the control of amphiregulin expression in renal development.
An evolutionarily conserved cAMP response element (CRE) sequence exists close to the transcriptional start site of the amphiregulin gene. We recently (6, 49, 50) demonstrated a role for the CRE binding protein (CREB) in controlling hypoxia-regulated gene expression. CREB was initially described as a signal-dependent activator of genes such as somatostatin, via PKA-dependent phosphorylation of Ser133 (1, 31, 32). However, we (6, 49, 51) and others (56) have also reported that CREB may act as a repressor for genes including TNF-
. Thus CREB plays an ambiguous role in the regulation of transcription that appears to be gene specific. In each case, however, CREB binds to an 8-bp palindrome (5'-TGACGTCA-3') known as the CRE that regulates transcription.
Hypoxic sensitivity of the amphiregulin promoter is retained in a short fragment directly upstream from the TATA box that contains a sole CRE motif. Interestingly, this motif was recently demonstrated to mediate amphiregulin expression in response to prostaglandin E2 (43). We previously demonstrated (49, 51) that hypoxia alters CREB expression and subsequently transcriptional activity in intestinal epithelial cells, an event dependent on decreased activity of protein phosphatase-1
.
Thus hypoxia activates intestinal epithelial amphiregulin expression in transformed cells in a manner dependent on functional activity of a CRE motif situated 37 bp upstream of the transcriptional start site. We believe that hypoxia-elicited amphiregulin expression may contribute to continued cell proliferation in focal areas of hypoxia found in a range of epithelial tumors. Furthermore, this work highlights the role of CREB as a hypoxia-responsive transcriptional regulator that can function independently of the classic HIF-1-dependent pathway.
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Animal model of hypoxia. Tissues were obtained from Dr. Sean Colgan, Brigham and Womens Hospital, Boston, MA. Mice were exposed to hypoxia (8% atmospheric oxygen) for 04 h as described previously (51). This protocol was in accordance with National Institutes of Health guidelines for the use of live animals and was approved by the Institutional Animal Care and Use Committee at Brigham and Womens Hospital, Boston, MA. The receipt of these tissues was approved by the Animal Ethics Committee of The Conway Institute. After being exposed, colonic mucosal tissue was removed, dissected along the mesenteric border, washed, and snap frozen for further analysis.
Gene array analysis. Microarray analysis was carried out as described previously (27, 51) using T84 cells exposed to hypoxia (0, 6, and 18 h) with the balance of time in normoxia. The mRNA profile was assessed using quantitative gene chip expression arrays (Affymetrix, Santa Clara, CA; Ref. 27). This array experiment was carried out once, and any genes identified as putatively hypoxia inducible were confirmed by PCR and Western blot analysis as described below.
Western blotting. Western blotting was carried out with standard techniques as described previously (49). CREB was detected using immunoblotting with an anti-CREB antibody that recognizes total CREB levels (Cell Signaling). Phospho-EGFR was detected using a panel of antibodies that recognize different sites of phosphorylation (Biosource).
Transient transfection of cells. HeLa cells were grown to 90% confluence and transfected with 2 µg of amphiregulin promoter-luciferase reporter construct pGL2[C] (24). For HIF-1 and mutant HIF-1 overexpression, cells were transfected as described previously (25). In cotransfection studies, HeLa cells were transfected with 2 µg of the reporter pGL2[C] with or without 100, 200, or 400 ng of pCMV-CREB wild-type expression vector or pCMV-KCREB mutant expression vector (Clontech). The total amount of DNA in each transfection was 2.4 µg (pGL2Basic was used to supplement the total DNA to this level). All transfections were carried out with Effectene transfection reagent (Qiagen) according to the manufacturers guidelines. After transfection, the cells were incubated overnight at 37°C in a humidified atmosphere of 5% CO2. Fresh medium was then added to the cells. Forty-eight hours after transfection the cells were treated with normoxic or preequilibrated hypoxic (1% O2) medium and returned to the growth conditions described above. PMA (100 nM) treatment was for 8 h. After incubation of the cells in normoxic or hypoxic conditions for 22 h, whole cell extracts were harvested. Medium was aspirated, and cells were washed with 2 ml of 1x PBS (ice cold). Two hundred microliters of 1x lysis buffer (Stratagene) were added for 23 min at room temperature. The cells were then scraped, transferred into a microfuge tube, and placed on ice. Each sample was sonicated for 23 s and centrifuged at 20,000 g for 6 min at 4°C. The cell lysate was transferred into a fresh microfuge tube and allowed to warm to room temperature before being assayed for luciferase activity. One hundred microliters of room temperature luciferase substrate (Stratagene) were added to twenty microliters of lysate and mixed thoroughly by pipetting in a glass luminometer tube. Luminescence was measured using a luminometer (Berthold Technologies Junior LB 9509). All readings were normalized to protein (Bradford method; Bio-Rad).
In control experiments to determine equal transfection efficiency and demonstrate that the effects of CREB overexpression were specific for amphiregulin and not due to a general downregulation in transcriptional activity, cells were cotransfected with 1.5 µg of pGL2[C], 0.25 µg of pCMV-Renilla luciferase, and 100400 ng of pCMV-CREB or pCMV-KCREB. In the assay for Renilla luciferase activity, 50 µl of whole cell extract were added to 50 µl of Renilla luciferase substrate coelenterazine (Sigma).
Analysis of mRNA levels by RT-PCR. Confluent monolayers of T84 cells were exposed to normoxia or hypoxia for 018 h. Total cellular RNA was obtained with the RNeasy system (Qiagen) according to the manufacturers recommendations. One microgram of each sample was used for conversion into cDNA. Total RNA was reverse transcribed to cDNA using a first-strand cDNA synthesis kit for RT-PCR (Roche). Each RNA sample was denatured by being heated to 65°C for 15 min followed by 5-min incubation on ice. One microgram (5 µl) of total RNA was then added to 10 mM Tris, 50 mM KCl (pH 8.3), 5 mM MgCl2 containing 1 mM deoxynucleotide mix (dNTP), 1.6 µg of oligo-p(dT) primer, 50 U of RNase inhibitor, and 20 U of avian myeloblastosis virus reverse transcriptase. Each sample reaction volume was adjusted to 20 µl with sterile water. Conversion of each RNA sample to cDNA was achieved by being incubated at 25°C for 10 min followed by 1 h at 40°C and then 99°C for 5 min and subsequently being cooled to 4°C for 5 min. The cDNA was then stored at 20°C.
Each cDNA sample (5 µl) subsequently acted as a template for amplification of amphiregulin by PCR (50 µl). The components of each PCR contained 5 µl of cDNA in reaction buffer containing 50 mM KCl, 10 mM Tris·HCl (pH 9), and 1% Triton X-100 along with 1.5 mM MgCl2, 0.2 mM dNTPs (Promega), 50 pmol of the upstream primer (5'-ACCTACACTCTGGGAAGCTGA-3'), 50 pmol of the downstream primer (5'-AGCCAGGTATTTGTGGTTCG-3') (Genoysis), 1.25 U of Taq DNA polymerase (Invitrogen), and 34.2 µl of sterile water, for a total reaction volume of 50 µl. The amplification reaction included a 2-min denaturation at 94°C, followed by 22 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 1 min, with a final extension of 72°C for 5 min.
-Actin amplification of each sample cDNA was used as a control in the RT-PCR. The target gene sequence was amplified using 50 pmol of a primer mix (Continental Laboratory Products). The remaining components of each reaction were identical to those used to amplify amphiregulin mRNA. Each reaction was denatured at 95°C for 2 min; this was followed by 25 cycles of 94°C for 30 s, 55°C for 1 min, 72°C for 1 min, and a final extension at 72°C for 10 min. Each PCR product was visualized using a 1% agarose gel containing 0.5 µg/ml ethidium bromide (EtBr; Sigma).
For TNF-
and somatostatin RT-PCR, first-strand cDNA synthesis was performed with Superscript II (Invitrogen Life Technologies, Carlsbad, CA) under recommended conditions. Amplification of cDNA was performed using 1 µg of cDNA, 1.5 mM MgCl2, 0.2 mM dNTP, 100 nM primers, and 1 U of Taq polymerase (Amersham Biosciences, Piscataway, NJ) in a reaction volume of 50 µl and carried out in a PTC-200 thermal cycler (MJ Research, Waltham, MA). After an initial denaturation step at 94°C for 2 min, cycling was carried out with the following conditions: 94°C for 30 s, 55°C for 45 s, and 72°C for 30 s for up to 40 cycles, with a final elongation step at 72°C for 10 min. At the indicated cycle numbers, a 10-µl aliquot was withdrawn from the reaction vial and loaded onto a 2% agarose gel in 0.5x Tris-acetic acid-EDTA, stained with EtBr, and visualized under UV illumination. The up- and downstream primers for somatostatin were 5'-cccagactccgtcagtttc-3' and 5'-ccgggtttgagttagcagat-3', respectively. The up- and downstream primers for TNF-
were 5'-cgtctcctaccagaccaagg-3' and 5'-ccaaagtagacctgcccaga-3', respectively.
ELISA. Confluent monolayers of T84 cells were exposed to 0- to 18-h hypoxia. Conditioned medium from the cells was collected, and amphiregulin levels were quantified by capture ELISA. A 96-well plate was coated with 100 µl of mouse anti-human amphiregulin MAb (2 µg/ml; R & D Systems) and incubated overnight at room temperature. Wells were washed three times with 400 µl of wash buffer (0.05% Tween 20 in PBS; pH 7.4). Three hundred microliters of blocking buffer (PBS containing 1% bovine serum albumin, 5% sucrose, and 0.05% NaN3) were added at room temperature for 1 h. The blocking buffer was aspirated, and wells were washed three times. One hundred microliters of each sample or known standards (02,000 pg/ml) were added to the wells, covered with an adhesive strip, and incubated for 2 h at room temperature. Plates were washed three times before addition of 100 µl of 1:2,500 biotinylated human amphiregulin affinity-purified polyclonal detection antibody (R&D Systems) and incubation for 2 h at room temperature. Wells were washed three times. One hundred microliters of streptavidin-horseradish peroxidase (HRP) were then added to each well, and the plate was covered and incubated at room temperature for 20 min. After three washes, 100 µl of substrate solution containing a 1:1 mixture of H2O2 and tetramethylbenzidine (Sigma) were added. The plate was allowed to develop in the dark for 30 min. The reaction was stopped by the addition of 50 µl of 1 M H2SO4 (Sigma) to each well. Optical density was determined using spectrophotometry at 450 nm with 570 nm as reference filter. The amphiregulin levels in each sample were determined using elucidation from the standard curve.
DNA binding assays. To investigate HIF-1 and CREB binding to consensus hypoxia response element (HRE) and CRE sequences, we used an ELISA-based approach according to the manufacturers instructions (TransAm Active Motif). Briefly, T84 cells were exposed to increasing periods of hypoxia, and nuclear extracts were prepared. Extracts were incubated in 96-well plates that contained bound oligonucleotides containing either the CRE or the HRE consensus motif. After the capture of the relevant transcription factor by the oligonucleotide, a primary antibody to either HIF-1 or CREB was added. An HRP-conjugated secondary antibody was used to quantify the DNA binding activity of the transcription factor in question. In separate studies, protein-DNA interaction analysis was carried out with EMSA as described previously (25).
Statistical analysis. All data are presented as means ± SE for n independent experiments. Statistical significance (P < 0.05) was evaluated using Students t-test for paired data.
| RESULTS |
|---|
|
|
|---|
|
-Actin mRNA levels remained stable. In a parallel study, cell supernatants were harvested from T84 cells exposed to hypoxia and assayed for amphiregulin protein levels using an in-house ELISA that we developed for the purpose of this experiment. The levels of amphiregulin secreted into the cell supernatant increased significantly in hypoxia (6 and 18 h; P < 0.05) compared with normoxic controls (Fig. 1C). Furthermore, hypoxia-induced amphiregulin release is in a basolaterally polarized direction (Fig. 1D). To confirm the physiological relevance of our in vitro observations, we investigated the impact of hypoxia on amphiregulin expression in mucosal tissue from mice exposed to increasing periods of hypoxia (04 h). Hypoxia caused an increase in mucosal amphiregulin levels at 2 h that was resolved by 4 h (Fig. 1E). The transient nature of this response is indicative of the induction of a physiological adaptation to tissue hypoxia. mRNA levels of the classically hypoxia-responsive gene VEGF as determined using real-time PCR analysis demonstrate a 3.13-fold increase at 2 h of hypoxia, confirming the perception of hypoxia by the tissue (data not shown). As a readout of amphiregulin activity, T84 cells treated overnight in hypoxia were examined for the phosphorylation of the EGF receptor (Fig. 1F). Hypoxia caused detectable phosphorylation at Tyr1173 and Tyr845 but not at Tyr1068 or Tyr1448.
Transcriptional mechanisms underlying hypoxia-induced amphiregulin.
We next investigated the transcriptional regulatory elements in the amphiregulin promoter that control expression in hypoxia. Initially, we examined the classic hypoxia-dependent activation of HIF-1
. HIF-1
was increased in hypoxia in HeLa cells in a time-dependent manner as demonstrated by transcription factor ELISA, which measures HIF-1-DNA binding (Fig. 2A). This response was consistent in a number of cell types including T84, HeLa, and HK-2 human kidney cells (data not shown). However, overexpression of wild-type HIF-1
or a constitutively active stable mutant, which was sufficient to induce the expression of known HIF-1 targets such as adrenomedullin, did not induce amphiregulin mRNA (Fig. 2B). This indicates an alternative mechanism for hypoxia-elicited amphiregulin expression.
|
We investigated the molecular mechanisms underlying increased amphiregulin expression in hypoxia. Addition of the cAMP analog 8-bromo-cAMP, which activates the phosphorylation of CREB at Ser133, had only mild effects on amphiregulin expression (Fig. 3A), indicating that the phosphorylation of CREB at Ser133 is not the primary mechanism of hypoxia-induced activity. Because of difficulties in T84 cell transfection, we used HeLa cells for these studies. Amphiregulin promoter luciferase reporters containing fragments of the promoter 612 bp (pGL2[A]) and 37 bp (pGL2[C]) upstream from the TATA box were transiently transfected into HeLa cells (21). PMA (100 nM) was used as a positive control to activate the amphiregulin promoter after transfection (45). We demonstrated previously (26) that both hypoxia and PMA (100 nM) activated pGL2[A] to stimulate luciferase transcription (3- to 4-fold), indicating that this larger fragment [which contains both the CRE and WT1 response element (WRE) motifs] contains a hypoxia-sensitive sequence. Absolute luciferase activity was generally higher in cells expressing the pGL2[A] construct compared with those expressing the pGL2[C] construct (data not shown). This implicates a role for the WRE in the regulation of basal promoter activity. However, qualitatively similar responsiveness to hypoxia is retained in the pGL2[C] promoter fragment that contains only the CRE 37 bp upstream from the TATA box (2.5- to 3-fold; Fig. 3B). Notably, although hypoxia sensitive, this sequence contains no HRE motifs. To determine the importance of the CRE sequence in conferring hypoxic sensitivity in the amphiregulin promoter, we used a pGL2[C] construct in which the CRE was deleted (pGL2[
C]). This deletion within the CRE significantly decreased, but did not abolish, basal promoter activity by 77.3 ± 2.9% (P < 0.05) and abolished the responsiveness to both hypoxia and 100 nM PMA (Fig. 3C). Thus the CRE 37 bp upstream from the TATA box of the amphiregulin gene is critical in the hypoxic sensitivity of the promoter.
|
. Thus the role of CREB as an activator or repressor of gene transcription appears to be gene specific. Semiquantitative PCR analysis of T84 cells exposed to increasing periods of hypoxia demonstrated downregulation in somatostatin mRNA expression and a coincidental upregulation in TNF-
expression (Fig. 4A). These data would indirectly support a role for decreased CREB activity in hypoxia. Because of this ambiguous role for CREB, we investigated the mechanism by which it controls amphiregulin gene expression in hypoxia.
|
gene expression in intestinal epithelial cells in hypoxia.
HIF-1 does not bind to unmasked CRE.
HIF-1 normally binds to the HRE, and CREB normally binds to the CRE. However, previous studies demonstrated cross-specificity for CREB and HIF-1 in binding to CRE and HRE motifs (11, 21, 22). Furthermore, within the CRE sequence exists a core motif that is 80% similar to the HRE. Because of this, we investigated the possibility that HIF-1, which is increased in hypoxia, might bind to a sequence within the unmasked CRE in the amphiregulin promoter to induce transcription. To investigate this possibility, we used specific transcription factor ELISAs for both HIF-1 and CREB binding to consensus HRE and CRE sequences, respectively. In increasing periods of hypoxia, quantifiable HIF-1-HRE binding occurred (Fig. 2A). As we have previously described (49), CREB DNA binding activity to the consensus CRE (100% similar to that in amphiregulin) was decreased in a time-dependent manner (data not shown). In cross-binding experiments, increasing periods of hypoxia did not increase HIF-1 binding to the amphiregulin CRE motif (Fig. 5A), indicating that HIF-1 binding is not an initiating factor in the control of CRE-dependent amphiregulin gene expression in hypoxia. Furthermore, using gel shift analysis, we demonstrated a hypoxia-dependent decrease in CREB-CRE binding with a concomitant increase in the binding of a protein of lower molecular mass (Fig. 5B). Future studies will identify this protein; however, the fact that it is smaller than CREB (42 kDa) rules out the possibility that it is HIF-1
(which has a molecular mass of 125 kDa).
|
| DISCUSSION |
|---|
|
|
|---|
The impact of hypoxia on cellular proliferation differs depending on cell type. Fibroblast and B lymphocyte proliferation is decreased in a manner dependent on HIF-1 activation (15). In contrast, endothelial and smooth muscle cell proliferation is increased in hypoxia (17, 38). Furthermore, the induction of angiogenic events in hypoxia mediated through the HIF-1-dependent expression of VEGF has been documented extensively (42). These contrasting effects on cell proliferation may be accounted for by differing transcriptional profiles activated by hypoxia in different cell types.
Activation of the EGFR is a potent stimulus for epithelial cell proliferation (34). Microarray analysis confirmed the basal expression of the EGFR in T84 cells as previously described (20). In injury, epithelial cell proliferation was recently described to be due to the association of EGF ligand and receptor, which are normally separated by the tight junction in the polarized epithelium (53). This process aids reestablishment of the epithelial barrier through a rapidly activated proliferative response that is then silenced upon reformation of a polarized monolayer. In this study, we have demonstrated that hypoxia increases the expression of amphiregulin in transformed intestinal epithelial cells in vitro and in colonic mucosal tissue from mice exposed to whole body hypoxia. Amphiregulin is an EGFR ligand that was shown previously to increase proliferation in a range of cell types (10, 19). Furthermore, amphiregulin expression is increased in tumors and in wound healing (8, 28, 39). Because hypoxia is also a feature of tumor development and wound healing, we became interested in the mechanism by which hypoxia upregulates intestinal epithelial amphiregulin expression.
To date, the regulation of amphiregulin gene transcription is not fully understood; however, the transcription factor WT1 has been demonstrated to regulate expression in the developing kidney (24). Truncations of the amphiregulin promoter lacking the WT1 binding site but containing a conserved CRE sequence had a lower basal of activity but maintained sensitivity to upregulation by hypoxia. These data indicate that although WRE activity is important in the maintenance of basal amphiregulin expression, hypoxic sensitivity is conferred by the CRE sequence.
Amphiregulin and TNF-
are both upregulated in hypoxia in a CRE-dependent manner. Interestingly, both the amphiregulin CRE (274 to 267) and the TNF-
CRE (106 to 109) lie within 100 bp of the TATA box, the suggested region of functional relevance. Both amphiregulin and TNF-
CRE sequences are the same consensus 8-bp palindrome 5'-TGACGTCA-3'. The inducibility of both of these genes by hypoxia is dependent on the removal of CREB, and each gene is induced to approximately the same level.
Although CREB-CRE binding is constitutive, cAMP-dependent phosphorylation of Ser133 by PKA results in transactivation and subsequent transcription of specific genes such as somatostatin (31, 55). This promotes transcription through interaction with coactivators such as CBP and ultimately with the basal transcription complex to drive gene expression (31). Interestingly, in hypoxia, cAMP levels are significantly diminished, indicating that PKA-mediated Ser133 phosphorylation and subsequent transactivation are unlikely to account for the effects of hypoxia on amphiregulin expression (49). Furthermore, we demonstrate that the addition of the cAMP analog 8-bromo-cAMP has only mild effects on amphiregulin expression. Previous studies in neurons demonstrated a phosphorylation of Ser133 of CREB in acute hypoxia in neurons (2); however, we have found that longer periods of hypoxia do not alter Ser133 phosphorylation in our model (49).
CREB was previously reported to act as a repressor of transcription for some genes (5). Members of the CREB family of proteins have also been shown to bind activator protein (AP-1) target DNA sequences, thus inhibiting AP-1-mediated transcription in differentiating keratinocytes (18, 37). We (49, 51) and others (56) have found evidence to support a role for diminished CREB repressor activity in hypoxia-induced expression of proinflammatory genes such as TNF-
in intestinal epithelial cells. We have demonstrated (51) that CREB is targeted to degradation in a phosphorylation-dependent manner, leading to the induction of gene transcription.
Because of the ambiguous nature of CREB-dependent transcriptional control, we investigated whether CREB acts as a stimulated activator or diminished repressor of amphiregulin gene expression in hypoxia. CREB-CRE binding is decreased in hypoxia, and overexpression of wild-type (CREB) but not mutant (KCREB) overcame the hypoxic induction of amphiregulin promoter activation. These findings support the idea that CREB acts as a tonic repressor of amphiregulin expression, which is removed in hypoxia, allowing transcription to occur.
Because hypoxia-elicited decrease of CREB binding to the sole CRE in the amphiregulin promoter is sufficient to drive transcriptional upregulation, we hypothesized that some other as yet unidentified transcription factor might bind to the unmasked CRE to initiate the formation of the basal transcriptional complex. A number of studies have demonstrated cross-specificity between HIF-1 and CREB at the level of binding to HRE and CRE sequences (4, 11, 21, 22). Specifically, CREB has been shown to have binding affinity for the HRE sequence and may be of importance in the hypoxic upregulation of genes such as lactate dehydrogenase. Furthermore, the CRE consensus motif (5'-TGACGTCA-3') contains within it a sequence 80% similar to the HRE consensus motif (5'-RCGTG-3'). For these reasons, we investigated whether HIF-1 that accumulated in these cells in hypoxia bound to the unmasked CRE. Using a recently developed DNA-binding ELISA approach, we demonstrated that although HIF-1 activity is indeed increased in hypoxia, HIF-1 does not bind to the amphiregulin CRE in hypoxia. Furthermore, overexpression of HIF-1
, which induces HIF-1-dependent genes, does not alter amphiregulin expression. Initial gel shift analysis demonstrates the possibility that another protein might bind the CRE in a hypoxia-dependent manner. Future studies will identify such potential hypoxia-sensitive transcriptional regulators, which might bind to the unmasked CRE in the induction of the transcriptional complex.
In summary, this study demonstrates for the first time that hypoxia upregulates intestinal epithelial amphiregulin expression in a basolaterally polarized manner, an event that may be of significance in the regulation of epithelial proliferation in wound healing and/or tumor development where hypoxia occurs. Furthermore, hypoxia-induced amphiregulin is dependent on the liberation of CREB repressor activity and independent of the classic HIF-1-dependent transcriptional pathway.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
2. Beitner-Johnson D and Millhorn DE. Hypoxia induces phosphorylation of the cyclic AMP response element-binding protein by a novel signaling mechanism. J Biol Chem 273: 1983419839, 1998.
3. Blanchet S, Rangolam K, Baulig A, Marano F, and Baeza-Squiban A. Fine particulate matter induces amphiregulin secretion by bronchial epithelial cells. Am J Respir Cell Mol Biol 30: 421427, 2004.
4. Braun L, Kardon T, Reisz-Porszasz ZS, Banhegyi G, and Mandl J. The regulation of the induction of vascular endothelial growth factor at the onset of diabetes in spontaneously diabetic rats. Life Sci 69: 25332542, 2001.[CrossRef][ISI][Medline]
5. Collins-Hicok J, Lin L, Spiro C, Laybourn PJ, Tschumper R, Rapacz B, and McMurray CT. Induction of the rat prodynorphin gene through Gs-coupled receptors may involve phosphorylation-dependent derepression and activation. Mol Cell Biol 14: 28372848, 1994.
6. Comerford KM, Leonard MO, Karhausen J, Carey R, Colgan SP, and Taylor CT. Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. Proc Natl Acad Sci USA 100: 986991, 2003.
7. Cuttitta F, Pio R, Garayoa M, Zudaire E, Julian M, Elsasser TH, Montuenga LM, and Martinez A. Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microsc Res Tech 57: 110119, 2002.[CrossRef][ISI][Medline]
8. DAntonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR, Iaffaioli VR, Salomon DS, and Normanno N. Transforming growth factor
, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas. Int J Oncol 21: 941948, 2002.[ISI][Medline]
9. Elson DA, Ryan HE, Snow JW, Johnson R, and Arbeit JM. Coordinate up-regulation of hypoxia inducible factor (HIF)-1
and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res 60: 61896195, 2000.
10. Falk A and Frisen J. Amphiregulin is a mitogen for adult neural stem cells. J Neurosci Res 69: 757762, 2002.[CrossRef][ISI][Medline]
11. Firth JD, Ebert BL, and Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 270: 2102121027, 1995.
12. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, and Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 46044613, 1996.[Abstract]
13. Furuta GT, Turner JR, Taylor CT, Hershberg RM, Comerford K, Narravula S, Podolsky DK, and Colgan SP. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med 193: 10271034, 2001.
14. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, Gassmann M, and Cuttitta F. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 14: 848862, 2000.
15. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, and Johnson RS. Hypoxia-inducible factor 1
is essential for cell cycle arrest during hypoxia. Mol Cell Biol 23: 359369, 2003.
16. Huang LE and Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 278: 1957519578, 2003.
17. Humar R, Kiefer FN, Bernws H, Resink TJ, and Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 16: 771780, 2002.
18. Jang SI and Steinert PM. Loricrin expression in cultured human keratinocytes is controlled by a complex interplay between transcription factors of the Sp1, CREB, AP1, and AP2 families. J Biol Chem 277: 4226844279, 2002.
19. Kato M, Inazu T, Kawai Y, Masamura K, Yoshida M, Tanaka N, Miyamoto K, and Miyamori I. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5. Biochem Biophys Res Commun 301: 11091115, 2003.[CrossRef][ISI][Medline]
20. Keely SJ, Uribe JM, and Barrett KE. Carbachol stimulates transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T84 cells. Implications for carbachol-stimulated chloride secretion. J Biol Chem 273: 2711127117, 1998.
21. Kvietikova I, Wenger RH, Marti HH, and Gassmann M. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res 23: 45424550, 1995.
22. Kvietikova I, Wenger RH, Marti HH, and Gassmann M. The hypoxia-inducible factor-1 DNA recognition site is cAMP-responsive. Kidney Int 51: 564566, 1997.[ISI][Medline]
23. Lah JJ and Frishman WH. Adrenomedullin: a vasoactive and natriuretic peptide with therapeutic potential. Heart Dis 2: 259265, 2000.[Medline]
24. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, and Haber DA. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98: 663673, 1999.[CrossRef][ISI][Medline]
25. Leonard MO, Cottell DC, Godson C, Brady HR, and Taylor CT. The role of HIF-1
in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J Biol Chem 278: 4029640304, 2003.
26. Leonard MO, OReilly SM, Comerford KM, and Taylor CT. Identification of cyclic AMP response element-binding protein-dependent transcriptional responses in hypoxia by microarray analysis. Methods Enzymol 381: 511524, 2004.[ISI][Medline]
27. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, and Brown EL. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14: 16751680, 1996.[CrossRef][ISI][Medline]
28. Ma L, de Roquancourt A, Bertheau P, Chevret S, Millot G, Sastre-Garau X, Espie M, Marty M, Janin A, and Calvo F. Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions. J Pathol 194: 413419, 2001.[ISI][Medline]
29. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, and Ratcliffe PJ. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94: 81048109, 1997.
30. Maxwell PH and Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13: 2937, 2002.[CrossRef][ISI][Medline]
31. Mayr B and Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2: 599609, 2001.[CrossRef][ISI][Medline]
32. Montminy MR and Bilezikjian LM. Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328: 175178, 1987.[CrossRef][Medline]
33. Nguyen SV and Claycomb WC. Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun 265: 382386, 1999.[CrossRef][ISI][Medline]
34. Normanno N, Bianco C, De Luca A, and Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci 6: D685D707, 2001.[ISI][Medline]
35. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ, and Shoyab M. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 10: 19691981, 1990.
36. Podolsky DK. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J Gastroenterol 35: 6974, 2000.[CrossRef][ISI][Medline]
37. Rutberg SE, Adams TL, Olive M, Alexander N, Vinson C, and Yuspa SH. CRE DNA binding proteins bind to the AP-1 target sequence and suppress AP-1 transcriptional activity in mouse keratinocytes. Oncogene 18: 15691579, 1999.[CrossRef][ISI][Medline]
38. Schafer M, Ewald N, Schafer C, Stapler A, Piper HM, and Noll T. Signaling of hypoxia-induced autonomous proliferation of endothelial cells. FASEB J 17: 449451, 2003.
39. Schelfhout VR, Coene ED, Delaey B, Waeytens AA, De Rycke L, Deleu M, and De Potter CR. The role of heregulin-
as a motility factor and amphiregulin as a growth factor in wound healing. J Pathol 198: 523533, 2002.[CrossRef][ISI][Medline]
40. Semenza GL, Nejfelt MK, Chi SM, and Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc Natl Acad Sci USA 88: 56805684, 1991.
41. Semenza GL. Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol Oncol Clin North Am 8: 863884, 1994.[ISI][Medline]
42. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laughner E, Ravi R, Simons J, Taghavi P, and Zhong H. "The metabolism of tumours": 70 years later. Novartis Found Symp 240: 251260, 2001.[Medline]
43. Shao J, Lee SB, Guo H, Evers BM, and Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63: 52185223, 2003.
44. Shoyab M, McDonald VL, Bradley JG, and Todaro GJ. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 85: 65286532, 1988.
45. Shoyab M, Plowman GD, McDonald VL, Bradley JG, and Todaro GJ. Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 243: 10741076, 1989.
46. Smith DM, Coppock HA, Withers DJ, Owji AA, Hay DL, Choksi TP, Chakravarty P, Legon S, and Poyner DR. Adrenomedullin: receptor and signal transduction. Biochem Soc Trans 30: 432437, 2002.[CrossRef][ISI][Medline]
47. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, and Colgan SP. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110: 9931002, 2002.[CrossRef][ISI][Medline]
48. Taylor CT, Dzus AL, and Colgan SP. Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor alpha. Gastroenterology 114: 657668, 1998.[CrossRef][ISI][Medline]
49. Taylor CT, Fueki N, Agah A, Hershberg RM, and Colgan SP. Critical role of cAMP response element binding protein expression in hypoxia-elicited induction of epithelial tumor necrosis factor-
. J Biol Chem 274: 1944719454, 1999.
50. Taylor CT and Colgan SP. Therapeutic targets for hypoxia-elicited pathways. Pharm Res 16: 14981505, 1999.[CrossRef][ISI][Medline]
51. Taylor CT, Furuta GT, Synnestvedt K, and Colgan SP. Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. Proc Natl Acad Sci USA 97: 1209112096, 2000.
52. Thim L. Trefoil peptides: from structure to function. Cell Mol Life Sci 53: 888903, 1997.[CrossRef][ISI][Medline]
53. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, and Welsh MJ. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 422: 322326, 2003.[CrossRef][Medline]
54. Wang GL and Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 90: 43044308, 1993.
55. Yamamoto KK, Gonzalez GA, Biggs WH 3rd, and Montminy MR. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature 334: 494498, 1988.[CrossRef][Medline]
56. Zhao L and Brinton RD. Suppression of proinflammatory cytokines interleukin-1
and tumor necrosis factor-
in astrocytes by a V1 vasopressin receptor agonist: a cAMP response element-binding protein-dependent mechanism. J Neurosci 24: 22262235, 2004.
This article has been cited by other articles:
![]() |
R. Meyuhas, E. Pikarsky, E. Tavor, A. Klar, R. Abramovitch, J. Hochman, T. G. Lago, and A. Honigman A Key Role for Cyclic AMP-Responsive Element Binding Protein in Hypoxia-Mediated Activation of the Angiogenesis Factor CCN1 (CYR61) in Tumor Cells Mol. Cancer Res., September 1, 2008; 6(9): 1397 - 1409. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, S. Masri, S. Phung, and S. Chen The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop Cancer Res., April 1, 2008; 68(7): 2259 - 2265. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Aydin, S. Signorelli, T. Lechleitner, M. Joannidis, C. Pleban, P. Perco, W. Pfaller, and P. Jennings Influence of microvascular endothelial cells on transcriptional regulation of proximal tubular epithelial cells Am J Physiol Cell Physiol, February 1, 2008; 294(2): C543 - C554. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Montel, A. Gaultier, R. D. Lester, W. M. Campana, and S. L. Gonias The Low-Density Lipoprotein Receptor Related Protein Regulates Cancer Cell Survival and Metastasis Development Cancer Res., October 15, 2007; 67(20): 9817 - 9824. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||